0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessIn patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile. (Funded by Onyx Pharmaceuticals; ClinicalTrials.gov number, NCT01080391.).
A. Keith Stewart, S. Vincent Rajkumar, Meletios A Dimopoulos, Tamás Masszi, Ivan Špıčka, Albert Oriol, Roman Hájek, Laura Rosiñol, David S. Siegel, Georgi Mihaylov, Vesselina Goranova‐Marinova, Péter Rajnics, Aleksandr Suvorov, Rubén Niesvizky, Andrzej Jakubowiak, Jesús F. San Miguel, Heinz Ludwig, Michael Wang, Vladimír Maisnar, Jiří Minařík, William Bensinger, María-Victoria Mateos, Dina Ben‐Yehuda, Vishal Kukreti, Naseem J. Zojwalla, Margaret Tonda, Xinqun Yang, Biao Xing, Philippe Moreau, Antonio Palumbo (2014). Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. , 372(2), DOI: https://doi.org/10.1056/nejmoa1411321.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2014
Authors
30
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1056/nejmoa1411321
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
